retatrutide phase 2 results 2024 2025 The numbers from Lilly's 3 trial dropped this week and I haven't been able to stop thinking about them. Not only as a doctor but as a long-term GLP-1 user Percent of participants achieving liver

Tirzepatide is the first combination of entero-pancreatic hormones [dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) RA] that has been approved for T2D management based on the findings from the phase 3 SURPASS programme

In that report, the incidence of pancreatic cancer was also 2.9 and 2.7 times greater with exenatide and sitagliptin, respectively, compared to other oral antidiabetic medications

These are no longer fringe experiments

doi: 10.1080/00365521.1997.11720715 13 GillSRPopMDeboyRTEckburgPBTurnbaughPJSamuelBSet al

Medical relevance of common protein-altering variants in GPCR genes across 337,205 individuals in the UK Biobank